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Amyotrophic lateral sclerosis (ALS) is a neuro-
degenerative disease affecting the motor neu-
rons of the brain and spinal cord. The disease
is characterized by muscular atrophy and
weakness due to degeneration of spinal motor
neurons and by hyperreﬂexia after loss of cere-
bral cortical motor neurons. Approximately
5–10% of ALS cases have a family history of
ALS. The etiology of ALS remains largely
unknown, although genetic factors are likely
involved in the familial form (Al-Chalabi and
Leigh 2000). Environmental exposures have
also been considered as potential causes of
ALS (Nelson 1995–1996). We reported that
increased risk of ALS was associated with occu-
pational exposure to lead and with higher lev-
els of both bone and blood lead, suggesting a
potential role for lead exposure in the etiology
of ALS (Kamel et al. 2002).
Genetic susceptibility may modify the
relationship of ALS to lead exposure. A poten-
tially relevant gene is ALAD, found on chro-
mosome 9q34 (Kelada et al. 2001), which
codes for δ-aminolevulinic acid dehydratase
(ALAD), an enzyme involved in heme synthe-
sis in red blood cells. A G to C transversion at
position 177 of the coding region of ALAD
replaces a lysine with an asparagine at position
59 of the ALAD protein, creating a variant
allele ALAD 2 as opposed to the wild-type
allele ALAD 1 (Wetmur et al. 1991a). The
frequency of ALAD 2 is approximately 10%
in Caucasian populations (Kelada et al. 2001).
The ALAD enzyme is the principal lead-bind-
ing site in erythrocytes, and the ALAD 2 pro-
tein binds lead more tightly than does the
ALAD 1 protein (Bergdahl et al. 1997b). This
change alters the toxicokinetics of lead and
may modify risk associated with lead exposure
(Kelada et al. 2001).
VDR, another gene potentially affecting
susceptibility to lead, is found on chromo-
some 12q and codes for the vitamin D recep-
tor (VDR). One polymorphism in this gene
is found at a BsmI restriction site in the
intron separating exons VIII and IX (Zmuda
et al. 2000). Presence of the site is denoted by
b and absence by B. The BB genotype is
found in 10–20% of Caucasians (Cooper and
Umbach 1996). The BB genotype may be
associated with a less functional receptor,
thereby affecting calcium absorption and dis-
tribution in the body (Zmuda et al. 2000).
Vitamin D can also inﬂuence lead absorption
and distribution (Fullmer 1992), suggesting
that the BB genotype might also be associated
with uptake of lead or susceptibility to lead
toxicity. Because the polymorphism is located
in an intron and does not appear to affect
splicing (Zmuda et al. 2000), it is unlikely to
cause direct changes in VDR function, but it
may be in linkage disequilibrium with func-
tional variants within the VDR gene or in
another closely linked gene.
We used data from a case–control study
conducted in New England from 1993 to
1996 (Kamel et al. 2002) to investigate asso-
ciations of ALS with polymorphisms in
ALAD and VDR and the influence of geno-
type on the previously observed association of
ALS with lead exposure.
Materials and Methods
Population. We recruited cases from two
major referral centers in New England: the
Neuromuscular Research Unit at New
England Medical Center and the Neuro-
physiology Laboratory at Brigham and
Women’s Hospital (Boston, MA). Diagnosis
of ALS was based on criteria published by the
World Federation of Neurology (Brooks
1994) and confirmed by a board-certified
neurologist (T.L.M. or J.M.S.). Patients were
eligible if they had received an initial diagno-
sis of ALS within the 2 years before enroll-
ment, if they lived in New England at least
half the year, and if they spoke English and
were mentally competent. Population con-
trols were identified by random telephone
screening (Waksberg 1978) and were eligible
if they lived in New England at least half the
year, spoke English, and were mentally com-
petent. In addition, potential controls were
excluded if they had a physician diagnosis of
any neurodegenerative disease, neuropathy, or
post-polio syndrome. We frequency-matched
controls to cases so that the distributions of
the variables age, sex, and region within New
England were similar in the two groups.
The institutional review boards of the
National Institute of Environmental Health
Sciences, New England Medical Center,
Brigham and Women’s Hospital, Survey
Research Associates–Battelle (Durham, NC),
and CODA (Durham, NC) approved the
study. All participants gave informed consent.
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Previous studies have suggested that lead exposure may be associated with increased risk of
amyotrophic lateral sclerosis (ALS). Polymorphisms in the genes for δ-aminolevulinic acid dehy-
dratase (ALAD) and the vitamin D receptor (VDR) may affect susceptibility to lead exposure. We
used data from a case–control study conducted in New England from 1993 to 1996 to evaluate the
relationship of ALS to polymorphisms in ALAD and VDR and the effect of these polymorphisms on
the association of ALS with lead exposure. The ALAD 2 allele (177G to C; K59N) was associated
with decreased lead levels in both patella and tibia, although not in blood, and with an imprecise
increase in ALS risk [odds ratio (OR) = 1.9; 95% confidence interval (95% CI), 0.60–6.3]. We
found a previously unreported polymorphism in ALAD at an Msp1 site in intron 2 (IVS2+299G>A)
that was associated with decreased bone lead levels and with an imprecise decrease in ALS risk (OR
= 0.35; 95% CI, 0.10–1.2). The VDR B allele was not associated with lead levels or ALS risk. Our
ability to observe effects of genotype on associations of ALS with occupational exposure to lead or
with blood or bone lead levels was limited. These ﬁndings suggest that genetic susceptibility con-
ferred by polymorphisms in ALAD may affect ALS risk, possibly through a mechanism related to
internal lead exposure. Key words: δ-aminolevulinic acid dehydratase, amyotrophic lateral sclerosis,
genetic susceptibility, lead, vitamin D receptor. Environ Health Perspect 111:1335–1339 (2003).
doi:10.1289/ehp.6109 available via http://dx.doi.org/ [Online 1 April 2003]
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on demographic and lifestyle characteristics
using a structured interview administered by
trained personnel (Kamel et al. 2002). Of
those eligible, 71% of cases and 76% of con-
trols completed the interview. Information on
diet 5 years before interview was collected with
a food frequency questionnaire (Longnecker et
al. 2000). Interview-based variables considered
in the present study were age in years (continu-
ous variable), sex, region (outside vs. within
Boston city limits), education (≤ high school
vs. > high school), current physical activity
(hours per day spent sitting, lying down, or
sleeping; continuous variable), cigarette smok-
ing (ever smoked at least 100 cigarettes vs.
never smoked), alcohol use (ever had at least
10 drinks of beer, wine, or liquor vs. never),
occupational exposure to lead (ever had a job
that involved exposure to lead fumes, dust, or
particles 10 or more times vs. never), and daily
calcium intake in grams (continuous variable),
based on both food and supplements.
Measurement of blood and bone lead. We
invited all cases and a subset of the controls
who lived within 20 miles of the testing center
to come to the laboratory for collection of
blood samples and measurement of bone lead.
Response rates for this portion of the study
were 95% for cases and 41% for controls.
Controls who were invited but declined to
come in to the laboratory were similar in age,
sex, education, physical activity, smoking, and
alcohol use to those who participated (Kamel
et al. 2002). Blood lead (micrograms per
deciliter) was measured using graphite furnace
atomic absorption spectroscopy. Bone lead was
measured in the mid-tibial shaft and the patella
using in vivo K X-ray ﬂuorescence (K-XRF) as
previously described (Aro et al. 1994; Burger et
al. 1990; Kamel et al. 2002). The technique
provides an unbiased estimate of bone lead lev-
els as micrograms of lead per gram of bone
mineral. Negative estimates of bone lead con-
centration may be obtained when true values
are close to zero.
DNA isolation and genotyping. Genomic
DNA was isolated from ~9 mL of frozen whole
blood using Gentra PUREGENE reagents
(Gentra Systems, Minneapolis, MN). The
region surrounding the known ALAD poly-
morphic site was ampliﬁed using a slight modi-
fication of a published method (Hsieh et al.
2000) with identical primers. Amplification
reactions were performed in 50 µL total vol-
ume with 100 ng genomic DNA, 20 pmol of
each primer, 1× Qiagen polymerase chain reac-
tion (PCR) buffer containing Mg2+ (Qiagen,
Valencia, CA), 37.5 µM of each dNTP, and
2.5 U Taq polymerase (Life Technologies,
Carlsbad, CA). The cycling conditions were
94°C for 5 min followed by 35 cycles of 94°C
for 1 min, 56°C for 1 min, and 72°C for 1
min, with a final cycle at 72°C for 7 min.
A1 0-µL aliquot of each PCR solution was
digested with 20 U (2 µL) MspI restriction
enzyme (New England Biolabs, Beverly, MA)
in 2.5 µL 10× NEBuffer 2 (50 mM NaCl, 10
mM Tris-HCl, 1 mM dithiothreitol) with
10.5 µL water at 37°C for 3 hr. The digested
fragments were separated on a 2% agarose gel.
Diagnostic fragment sizes were 582 bp for
ALAD 1 and 511 bp + 71 bp for ALAD 2.
We also identified a novel polymorphism in
intron 2 of ALAD.
The region surrounding the known VDR
polymorphic site was amplified using previ-
ously described primers (Morrison et al.
1994). Amplification reactions were per-
formed in 35 µL total volume with 100 ng
genomic DNA, 10 pmol each of primer, 1×
BRL PCR buffer containing 1.75 mM Mg2+
(Life Technologies), 37.5 µM each dNTP,
and 2 U Taq polymerase (Life Technologies).
The cycling conditions were 94°C for 5 min
followed by 35 cycles of 94°C for 1 min, 60°C
for 1 min, and 72°C for 1 min, with a final
cycle at 72°C for 7 min. A 11.5 µL aliquot of
each PCR was digested with 20 U (2 µL)
BsmI restriction enzyme (New England
Biolabs) in 1.5 µL 10× NEBuffer 2 with 2 µL
water at 37°C for 3 hr. The digested frag-
ments were separated on a 1% agarose gel.
Diagnostic fragment sizes were 800 bp for B
and 650 bp + 150 bp for b.
Data analysis. The present analysis, con-
ducted using SAS (version 8.2; SAS Institute,
Inc., Cary, NC), includes 103 cases and 38
controls who provided complete data. Lead lev-
els were modeled as continuous variables to
increase the statistical power of the analysis.
Blood lead levels below assay sensitivity were
assigned a value of 0.5 µg/dL, one-half the
detection limit. To remove extreme skewness in
bone lead distribution while accommodating
the few negative values, we transformed bone
lead concentrations using the function log2
(Pb + 32), where Pb is bone lead concentra-
tion in micrograms per gram (Kamel et al.
2002). Because few homozygotes were found
for either polymorphism in ALAD (Table 1),
ALAD genotypes were included as dichoto-
mous predictors, indicating the presence or
absence of the polymorphism. No evidence of
dose response was observed in models compar-
ing VDR bB or VDR BB to VDR bb, so results
are presented from models using dichotomous
predictors.
The relationship of genotype to blood or
bone lead levels was analyzed in the control
group alone because inclusion of cases might
have allowed disease to distort the relationship.
We used linear regression for these analyses,
with blood lead, log-transformed patella lead,
or log-transformed tibia lead as the depen-
dent variable. On the basis of preliminary
analyses, we considered the following inde-
pendent variables: age, square root of age,
sex, region, education, inactivity, cigarette
smoking, occupational exposure to lead, and
patella lead (for blood lead models only). We
used backward elimination to determine
which of these covariates to include in base
models, using p = 0.15 as a cutoff. The base
model for blood lead included variables for
age, sex, region, inactivity, cigarette smoking,
and patella lead; the base model for patella
lead included age and cigarette smoking; and
the base model for tibia lead included age,
sex, and region. Genotype variables were
added to these base models. Results of linear
regressions are presented as estimated coeffi-
cients with 95% confidence intervals (95%
CIs) based on standard errors.
We analyzed the relationship of ALS to
lead exposure or genotype using multiple
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Table 1. Distribution of polymorphisms in ALAD (n cases, n controls).
ALAD K59N
ALAD IVS2 + 299G > A 1-1 1-2 2–2 Total
I2-1, I2-1 68, 25 19, 5 2, 1 89, 31
I2-1, I2-2 12, 5 2, 1 0, 0 14, 6
I2-2, I2-2 0, 1 0, 0 0, 0 0, 1
Total 80, 31 21, 6 2, 1 103, 38
Table 2. Genotypes of ALS cases and controls.
Cases (n = 103) Controls (n = 38)
No. Percent No. Percent
ALAD K59N
1-1 80 78 31 82
1-2 21 20 6 16
2-2 221 3
ALAD IVS2+299G > A
mm 89 86 31 82
mM 14 14 6 16
MM 001 3
VDR
bb 33 32 10 26
bB 49 48 20 53
BB 21 20 8 21
Environmental Medicine | Kamel et al.logistic regression. All models included the
matching variables age, sex, and region. Both
education and current physical activity levels
were associated with case–control status and
also potentially related to blood and bone lead
levels, so models also included these variables.
VDR models were also constructed with or
without calcium intake. Associations are esti-
mated as odds ratios (ORs), and 95% CIs are
based on standard errors. No substantive dif-
ferences were found when familial cases were
excluded from the analyses, so results for all
participants are presented.
We used standard methods (Weir 1996) to
evaluate Hardy-Weinberg equilibrium at each
locus and to examine linkage disequilibrium
between the two polymorphisms in ALAD.
Results
Blood lead levels in study participants ranged
from < 1 to 14 µg/dL; patella lead levels from
–4 to 107 µg/g; and tibia lead levels from –7 to
61 µg/g (Kamel et al. 2002). Thirty-six percent
of cases and 21% of controls reported ever hav-
ing had a job involving lead exposure. Ninety-
six percent of cases and 92% of controls were
white and not Hispanic.
We found a novel polymorphism in
ALAD at an MspI site in intron 2; a G to A
transition at nucleotide 299 destroyed the
site (GeneSNPs 2003). Diagnostic fragment
sizes for ALAD IVS2+299G>A were 160 bp
and 138 bp for ALAD I2-1 and 298 bp for
ALAD I2-2. We confirmed the presence of
the polymorphism by sequencing (data not
shown); it was not located at a splice site. We
denote the polymorphism at position 177 by
ALAD K59N, and, following convention, its
alleles by ALAD 1 (wild type) and ALAD 2
(variant). We denote the intron 2 polymor-
phism by ALAD IVS2+299G>A and its alle-
les by ALAD I2-1 (wild type) and ALAD
I2-2 (variant). The relative distribution of the
two ALAD polymorphisms is shown in Table
1. We saw no evidence of linkage disequilib-
rium between ALAD K59N and ALAD
IVS2+299G > A in either cases (p = 0.3) or
controls (p = 0.5).
ALAD K59N genotype. We found no
deviation from Hardy-Weinberg equilibrium
for the two ALAD K59N alleles in either cases
(p = 0.7) or controls (p = 0.3). The genotype
frequencies are shown in Table 2. The fre-
quency of the ALAD 2 allele was 12% in cases
and 11% in controls; the crude OR for the
relationship of the variant allele to ALS was
1.3 (95% CI, 0.5–3.7). In controls, presence
of the allele was associated with decreases in
patella and tibia lead levels but not with
blood lead levels (Table 3). The ALAD 2
allele was not related to the distribution of
lead among the three lead compartments
(data not shown).
After adjustment for age, sex, region, edu-
cation, and physical activity, ALAD 2 was
associated with an approximately 2-fold
increase in risk of ALS, although the relation-
ship was imprecise (Table 4, model 1). The
association of ALAD 2 with ALS risk was
strengthened by further adjustment for blood
lead, although adjustment for patella or tibia
lead or occupational exposure to lead made
little difference (Table 5, model 5). ORs for
blood and bone lead and occupational lead
exposure were unchanged by adjustment for
ALAD 2 (Table 5, models 4 and 5). We saw
no important interaction of ALAD 2 with any
lead variable (data not shown). Results from
models that were not adjusted for physical
activity (data not shown) were similar to those
presented in Tables 4 and 5.
ALAD IVS2+299G>A genotype. We
found no deviation from Hardy-Weinberg
equilibrium for the two ALAD IVS2+299G>A
alleles in either cases (p = 0.5) or controls (p =
0.3). The genotype frequency is given in
Table 2. The frequency of the ALAD I2-2
allele was 7% in cases and 11% in controls;
the crude OR for the relationship of ALS to
the presence of the variant allele was 0.7
(95% CI, 0.2–2.1). In controls, presence of
the ALAD I2-2 allele was associated with
decreases in patella and tibia lead levels but
not with blood lead levels (Table 3).
After adjustment for age, sex, region, edu-
cation, and physical activity, presence of the
ALAD I2-2 allele was inversely associated
with ALS, with or without adjustment for
lead levels or occupational exposure to lead
(Table 4, model 2; Table 5, model 6). ORs
for blood and bone lead and occupational
lead exposure were unchanged by adjustment
for ALAD I2-2 (Table 5, models 4 and 6).
We saw a large but imprecise interaction
between ALAD I2-2 and lead variables that
was likely due to small numbers (data not
shown). Results from models that were not
adjusted for physical activity (data not shown)
were similar to those presented in Tables 4
and 5. In models including both ALAD 2 and
ALAD I2-2, ORs for both polymorphisms
were similar to those found in models with
only one genotype, whether or not lead vari-
ables were also included (data not shown).
VDR genotype. We found no deviation
from Hardy-Weinberg equilibrium for the two
VDR alleles in either cases or controls (p = 0.7
for each). The genotype frequency is given in
Table 2. The frequency of the B allele was
45% in cases and 48% in controls; the crude
OR for the presence of the variant allele was
0.8 (95% CI, 0.3–1.9). Presence of the allele
was not associated with either blood or bone
lead levels in controls (Table 3).
After adjustment for age, sex, region, edu-
cation, and physical activity, VDR B was not
related to ALS, without or with adjustment
for lead levels or occupational exposure to
lead (Table 4, model 3; Table 5, model 7).
ORs for blood and bone lead and occupa-
tional lead exposure were unchanged by
adjustment for VDR B (Table 5, models 4
and 7). Further adjustment for calcium intake
did not alter these relationships (data not
shown). We saw no important interaction of
VDR B with any lead variable (data not
shown). Results from models that were not
adjusted for physical activity (data not shown)
were similar to those presented in Tables 4
and 5. Results from models comparing VDR
bB or VDR BB with VDR bb were similar to
results using the dichotomous variable; we
found no evidence of a dose response (data
not shown).
Discussion
In this study, we found that the ALAD 2
allele (177G to C; K59N) and a previously
unidentiﬁed polymorphism at an MspI site in
intron 2 of ALAD, denoted ALAD I2-2, were
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Table 3. Associations of blood and bone lead levels with genotype in controls (n = 38).
ALAD K59N ALAD IVS2+299G > A VDR
Mean (95% CI) Mean (95% CI) Mean (95% CI)
1-1 2 p-Value mm M p-Value bb B p-Value
Blood lead (µg/dL) 3.0 2.8 0.76 2.9 2.9 0.95 2.9 3.0 0.82
(2.2–3.8) (1.6–4.0) (2.2–3.7) (1.7–4.2) (1.9–3.8) (2.2–3.8)
Patella lead (µg/g) 14 7.3 0.015 13 8.6 0.035 12 12 0.44
(9.0–18) (1.7–14) (8.3–18) (2.5–16) (5.8–18) (7.4–17)
Tibia lead (µg/g) 14 8.6 0.055 14 8.3 0.024 13 13 0.63
(10–18) (3.1–15) (10–17) (2.2–15) (7.3–19) (9.2–16)
Adjusted mean lead levels were calculated from linear regressions. Blood lead was modeled as micrograms per decaliter; patella and tibia lead were modeled as log2 (Pb + 32), where
Pb is bone lead concentration in micrograms per decaliter, and then transformed back to original units for presentation. Blood lead models included age, sex, region, physical activity,
ever smoked, and patella lead levels. Patella lead models included age and ever smoked. Tibia lead models included age, sex, and region. Mean lead levels are presented for 60-year-
old nonsmoking men from Boston with mean values of inactivity and patella lead. p-Values for the differences between means were calculated from the same linear regressions.
Environmental Medicine | ALS and ALADboth associated with decreased bone lead lev-
els but not with blood lead levels. ALAD 2
appeared to be associated with an increase and
ALAD I2-2 with a decrease in risk of ALS,
although both associations were imprecise. In
contrast, the VDR B allele showed no rela-
tionship to blood or bone lead levels or to
ALS risk.
Our ﬁnding that ALAD 2 was associated
with decreases in both tibia and patella lead
levels but not with blood lead levels is consis-
tent with some previous results. Some studies
have reported that blood lead levels were ele-
vated in ALAD 2 carriers, although the differ-
ences were not always statistically significant
(Alexander et al. 1998; Fleming et al. 1998;
Hsieh et al. 2000; Schwartz et al. 2000a;
Wetmur et al. 1991b; Ziemsen et al. 1986).
Other studies have found no difference in
blood lead levels between ALAD 1 homozy-
gotes and ALAD 2 carriers (Bergdahl et al.
1997a; Hu et al. 2001; Lee BK et al. 2001;
Schwartz et al. 1997; Smith et al. 1995a).
Any difference between genotypes in blood
lead levels is likely due to tighter binding of
lead to ALAD 2 than to ALAD 1 (Bergdahl et
al. 1997b) and may be evident only at higher
blood lead concentrations where other bind-
ing sites are saturated (Hu et al. 2001). Thus,
a difference would not necessarily be expected
at the relatively low blood lead concentrations
found in our study participants. ALAD 2 has
also been associated with decreased lead levels
in trabecular or cortical bone (Hu et al. 2001;
Smith et al. 1995b) and with decreased
uptake of lead into both bone compartments
(Fleming et al. 1998), although other studies
found no relationship (Bergdahl et al. 1997a;
Lee BK et al. 2001; Schwartz et al. 2000a).
Overall these ﬁndings are consistent with
the hypothesis that ALAD 2 alters the toxico-
kinetics of lead, promoting retention of lead
in blood and migration of lead from bone to
blood. The implications for lead toxicity are
unclear. Tighter binding to ALAD 2 in red
blood cells could make lead less available to
target tissues and hence less toxic. On the
other hand, increased retention of lead in
blood relative to bone might increase its avail-
ability to target tissues. Our data suggesting
that ALAD 2 was positively associated with
ALS are consistent with the latter hypothesis.
The effect of the ALAD 2 allele on lead
toxicokinetics might in theory modify associa-
tions of ALS with indices of internal exposure
(blood and bone lead) or external exposure
(occupational exposure). We found no evi-
dence to support either of these possibilities.
The ALAD 2 polymorphism did not alter the
relationship of blood or bone lead to ALS or
the risk associated with occupational exposure
to lead. However, our study had limited
power to evaluate effect modification, and
this issue needs further consideration.
Few previous studies have examined the
effect of ALAD 2 on health outcomes. ALAD 2
had no consistent relationship to hematologic
parameters (Alexander et al. 1998; Lee SS et al.
2001; Schwartz et al. 1995; Sithisarankul et al.
1997; Smith et al. 1995a) or to blood pressure
or hypertension (Lee BK et al. 2001; Smith et
al. 1995b). One study found detrimental
effects of ALAD 2 on renal function (Smith et
al. 1995b) and another found better perfor-
mance on a test of attention in ﬁve carriers of
the allele (Bellinger et al. 1994). A recent study
found that ALAD 2 modiﬁed the association of
bone lead levels with indices of renal function
(Wu et al. 2003), but other studies have not
detected effect modiﬁcation (Alexander et al.
1998; Lee BK et al. 2001; Lee SS et al. 2001).
We found no association of VDR B with
blood or bone lead levels or with ALS. In sev-
eral studies of a group of Korean lead workers,
Schwartz and colleagues found that VDR B
was associated with an increase in blood and
tibia lead levels and with increased blood pres-
sure and hypertension, although not with
hematopoietic outcomes (Lee BK et al. 2001;
Lee SS et al. 2001; Schwartz et al. 2000a).
VDR B did not modify the effect of lead on
blood pressure and hypertension (Lee BK
et al. 2001) but was weakly associated with a
decreased effect of lead on hemoglobin and
hematocrit (Lee SS et al. 2001). In another
cohort, VDR B had only minimal effects on
tibia lead levels but increased the accumula-
tion of tibia lead with age (Schwartz et al.
2000b). Understanding the relationship of
this polymorphism to lead toxicokinetics thus
awaits further study.
It is unclear why previous studies of
ALAD 2 have not reported the MspI polymor-
phism in intron 2. The 2% agarose gels we
used to separate the reaction products may
provide better resolution of the shorter frag-
ments associated with this polymorphism.
Nor is it clear why ALAD IVS2+299G>A, an
intronic variant, is associated with changes in
bone lead levels or with ALS. The associations
do not appear to be the result of strong linkage
or other interaction with the ALAD K59N
site. Recent work has demonstrated that
intronic mutations can have functional conse-
quences in some genes—for example, p53
(Lehman et al. 2000).
Our study is limited by the low participa-
tion rate of controls in the laboratory portion of
the study. This problem raises concerns about
selection bias and also reduces the power of the
study, contributing to the imprecision of some
estimates. However, none of the three geno-
types was seen to deviate from Hardy-
Weinberg equilibrium, and frequencies of
ALAD 2 and VDR B were similar to reported
values (Cooper and Umbach 1996; Kelada et
al. 2001). Further, controls who were invited
but declined to participate in the lab portion of
the study were similar in all characteristics
examined to those who participated (Kamel et
al. 2002). We therefore regard it as unlikely
that the association of ALS with ALAD geno-
type can be explained entirely by selection bias.
Previously we reported that ALS risk was
associated with increases in both blood and
bone lead levels (Kamel et al. 2002). The asso-
ciation with blood lead was surprisingly
strong, with a 2-fold increase in risk for each
microgram per decaliter increase in blood lead
levels. Although selection bias might have
influenced our results, some of the potential
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Table 5. Associations of ALS with genotype [(adjusted OR (95% CI)]: models with lead variables.
Occupational
Models Blood Patella Tibia exposure
Model 4
Lead 1.9 (1.4–2.6) 3.6 (0.62–21) 2.3 (0.37–14) 2.2 (0.68–7.3)
Model 5
Lead 2.0 (1.4–2.8) 3.8 (0.65–22) 3.0 (0.43–21) 2.7 (0.79–9.1)
ALAD 2 3.6 (0.9–15) 2.1 (0.61–6.9) 2.2 (0.66–7.3) 2.4 (0.67–8.7)
Model 6
Lead 1.8 (1.3–2.6) 3.4 (0.58–20) 2.3 (0.35–15) 2.2 (0.67–7.1)
ALAD I2-2 0.47 (0.12–1.8) 0.37 (0.10–1.3) 0.35 (0.10–1.2) 0.29 (0.1–1.2)
Model 7
Lead 1.9 (1.4–2.7) 4.1 (0.69–24) 2.2 (0.35–14) 2.1 (0.63–7.1)
VDR B 0.52 (0.15–1.7) 0.60 (0.20–1.8) 0.70 (0.24–2.0) 0.79 (0.26–2.4)
ORs for ALS were calculated using logistic regression for each unit increase in blood lead or log-transformed bone lead or
for self-reported occupational exposure to lead. Blood lead was modeled as micrograms per deciliter and patella and tibia
lead as log2 (Pb + 32), where Pb is bone lead concentration in micrograms per gram. In addition to the indicated variables,
all models included age, square root of age, sex, region, education, and physical activity.
Table 4. Associations of ALS with genotype: models
without lead variables.
Models Adjusted OR (95% CI)
Model 1
ALAD 2 1.9 (0.60–6.3)
Model 2
ALAD I2-2 0.35 (0.10–1.2)
Model 3
VDR B 0.68 (0.24–1.9)
ORs for ALS were calculated using logistic regression for
each unit increase in blood lead or log-transformed bone
lead or for self-reported occupational exposure to lead.
Blood lead was modeled as micrograms per deciliter and
patella and tibia lead as log2 (Pb + 32), where Pb is bone
lead concentration in micrograms per gram. In addition
to the indicated variables, all models included age,
square root of age, sex, region, education, and physical
activity.
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biases, if present, would likely have minimized
the association of ALS with blood lead rather
than creating a spurious relationship (Kamel et
al. 2002). Blood lead is often considered to
reflect recent exposure. However, in adults
without current exogenous exposure, like most
of the participants in our study, bone lead is
the major source of blood lead (Hu et al.
1998). The latter may therefore reﬂect cumu-
lative lifetime exposure. Blood lead levels are
determined by bone lead levels together with
factors affecting mobilization of lead from
bone. The present study suggests that ALAD
genotype may be one such factor, whereas
VDR genotype does not appear to be impor-
tant. Alterations in lead toxicokinetics con-
ferred by the presence of the ALAD 2 allele
may subtly increase exposure to lead through-
out a person’s lifetime, thereby elevating risk.
We cannot exclude the possibility that ALAD
2 affects ALS risk through some mechanism
independent of lead exposure, perhaps
through an unidentified polymorphism in
linkage disequilibrium with the ALAD 2 site.
However, the association of ALAD 2 with
decreased bone lead levels suggests that lead
may play some role.
In conclusion, our study suggests that
genetic susceptibility conferred by ALAD 2 is
associated with ALS risk, possibly through a
mechanism related to lead exposure. Because our
study is small, and the observation is unique,
this hypothesis needs further consideration.
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